Business Pipeline How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup BioPharma DiveCohen says he looked at around two dozen companies since Acorda wound down.PipelineNeuroscienceRead full story pharminent March 24, 2026 (Last updated: March 24, 2026) BioPharma Dive Cohen says he looked at around two dozen companies since Acorda wound down. PipelineNeuroscience Read full story Post navigation Previous: Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study resultsNext: NOW AVAILABLE: The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers Related Stories Pipeline Amgen positions MariTide as potential ‘best monthly’ obesity drug pharminent May 1, 2026 Pipeline Merck still sees ‘compelling’ outlook for Terns leukemia drug pharminent April 30, 2026 Pipeline AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolio pharminent April 30, 2026
